Siemens Healthineers AG reported comparable revenue growth of 4.0 per cent in fiscal year 2026, supported by a strong fourth quarter in which revenue increased 5.9 per cent on a comparable basis. The company is expecting further revenue growth of 4.0 to 5.0 per cent in fiscal year 2027, while continuing to strengthen its core businesses and reposition its Diagnostics segment.
“We closed out the last fiscal year with a strong fourth quarter. In this new fiscal year, we are shaping our next phase with a different shareholder structure, and enhancing corporate clarity,” said Bernd Montag, CEO of Siemens Healthineers AG.
For fiscal year 2026, the company's adjusted EBIT margin stood at 16.2 per cent, with adjusted EBIT reaching approximately €3.8 billion. Adjusted basic earnings per share were €2.42, while free cash flow amounted to approximately €2.4 billion. The equipment book-to-bill ratio was 1.14, indicating equipment orders exceeded recognised revenue. Siemens Healthineers has proposed a dividend of €1.00 per share, unchanged from the previous year.
Fourth-quarter performance
In the fourth quarter of fiscal year 2026, Siemens Healthineers recorded a comparable revenue growth of 5.9 per cent, with an equipment book-to-bill ratio of 1.15. The adjusted EBIT margin was 15.9 per cent, while adjusted basic earnings per share stood at €0.69. Free cash flow for the quarter reached €703 million.
Among its business segments, Imaging delivered the strongest performance, with comparable revenue growth of 10.0 per cent and an adjusted EBIT margin of 21.9 per cent. Precision Therapy recorded comparable revenue growth of 4.8 per cent, with an adjusted EBIT margin of 13.8 per cent.
Diagnostics, meanwhile, reported a comparable revenue decline of 4.2 per cent and an adjusted EBIT margin of 5.4 per cent.
Strategic priorities and FY2027 outlook
The company is continuing to implement its ‘Elevating Health Globally’ strategy, with a focus on strengthening its core portfolio and expanding innovation in areas addressing prevalent non-communicable diseases.
As part of its portfolio realignment, Siemens Healthineers is initiating the carve-out process for its Diagnostics business, with the objective of positioning the segment for a successful future. The company is also advancing its planned brand evolution to Healthineers, reflecting its next phase under a different shareholder structure.
For fiscal year 2027, Siemens Healthineers expects comparable revenue growth of between 4.0 and 5.0 per cent compared with fiscal year 2026. Adjusted basic earnings per share are projected to be in the range of €2.20 to €2.40.
